Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
- Conditions
- C3 GlomerulopathyIgA Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT05083364
- Locations
- 🇹🇭
Research Site 3, Chiang Mai, Thailand
🇳🇿Research Site, Auckland, New Zealand
🇹🇭Research Site 2, Bangkok, Thailand
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 353
- Registration Number
- NCT04998201
- Locations
- 🇺🇸
Alta Pharmaceutical Research Center, Dunwoody, Georgia, United States
🇺🇸Preventive Cardiology Inc., Boca Raton, Florida, United States
🇺🇸A & R Research Group, Pembroke Pines, Florida, United States
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 204
- Registration Number
- NCT04832971
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸AGA Clinical Trials, Hialeah, Florida, United States
🇺🇸Medication Management LLC, Greensboro, North Carolina, United States
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 229
- Registration Number
- NCT04720534
- Locations
- 🇺🇸
Pioneer Research Solutions, Inc., Houston, Texas, United States
🇺🇸Clinical Research of South Nevada, Las Vegas, Nevada, United States
🇺🇸AppleMed Research Group, Miami, Florida, United States
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT04375514
- Locations
- 🇳🇿
Research Site, Dunedin, New Zealand
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: ARO-HSD InjectionDrug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT04202354
- Locations
- 🇳🇿
Auckland Clinical Studies, Grafton, Auckland, New Zealand
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2022-07-27
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT04169711
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT03946449
- Locations
- 🇬🇧
Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom
🇩🇪Universitatsklinikum Aachen, Anstalt des offentlich, Aachen, Germany
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Drug: Fazisiran InjectionOther: Placebo
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03945292
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Center for Health Sciences, Los Angeles, California, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of California San Diego Altman Clinical and Translational Research Institute, La Jolla, California, United States
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
- Conditions
- HypertriglyceridemiaFamilial Chylomicronemia
- Interventions
- Drug: sterile normal saline (0.9% NaCl)
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 112
- Registration Number
- NCT03783377
- Locations
- 🇦🇺
Linear Clinical Research, Perth, Western Australia, Australia
🇦🇺Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia